Form D · Pharmaceuticals
Neuvivo, Inc.
Palo Alto, CA · CIK 0002154992
Offering snapshot reported Nov 13, 2026 · SEC filing
- Reported sold
- $1.38M Offering amount: $9.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 30, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 13, 2026 | Initial | $1,384,615 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-604762
Source: Form D, filed Nov 13, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Baffi | Director |
| John Curnutte | Director |
| Michael Mc Grath | Director, Executive |
| Pornsit Poovanakijjakorn | Director |
| Virit Vichitvadakan | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2100 Geng Road Suite 210
Palo Alto, CA, 94303
Palo Alto, CA, 94303